Home/Filings/4/0001209191-20-001170
4//SEC Filing

De Groot Eleanor 4

Accession 0001209191-20-001170

CIK 0001107421other

Filed

Jan 2, 7:00 PM ET

Accepted

Jan 3, 5:06 PM ET

Size

5.5 KB

Accession

0001209191-20-001170

Insider Transaction Report

Form 4
Period: 2020-01-02
De Groot Eleanor
EVP, GM Cell Therapy
Transactions
  • Sale

    Common Stock

    2020-01-02$4.55/sh24,890$113,250174,333 total
Footnotes (2)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to satisfy withholding tax obligations upon the vesting of restricted stock grants.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.46 to $4.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Issuer

ZIOPHARM ONCOLOGY INC

CIK 0001107421

Entity typeother

Related Parties

1
  • filerCIK 0001780420

Filing Metadata

Form type
4
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 5:06 PM ET
Size
5.5 KB